2019-001301-24: Study to investigate the immune response and determine functional antibodies after a MenACWY-vaccination Studie naar de werkzaamheid van een MenACWY-vaccinatie bij volwassenen van 65 jaar en ouder |
|
|
| Not yet recruiting | 4 | 140 | Europe | Nimenrix, Powder and solution for solution for injection, Nimenrix | National Institute for Public Health and the Environment (RIVM), National Institute for Public Health and the Environment (RIVM) | The tetravelent MenACWY-TT vaccin administered in this study is used to prevent invasive disease caused by Meningococcal serogroup A, C, W and Y. Het tetravalente MenACWY-TT vaccin beschermt tegen invasieve meningokokkenziekte van type A, C, W en Y., Invasive meningococcal disease, meningitis, sepsis Invasieve meningokokkenziekte, hersenvliesontsteking, bloedvergiftiging, Diseases [C] - Bacterial Infections and Mycoses [C01] | | | | |
NCT05929651: Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy |
|
|
| Recruiting | 4 | 180 | RoW | MenACYW conjugate vaccine, MenQuadfi® | Sanofi Pasteur, a Sanofi Company | Meningococcal Immunisation, Healthy Volunteers | 09/24 | 09/24 | | |
